Overslaan en naar de inhoud gaan

Pharming announces the successful completion of patient enrolment in the  pivotal Phase II/III triple-blind, randomized, placebo-controlled study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).

With completion of enrolment, we move one step closer to making this medicine available for APDS patients around the world.

- Anurag Relan - Chief Medical Officer
Cookies: Deze website maakt gebruik van cookies. Bekijk de cookie instellingen pagina voor meer informatie Accepteren Weigeren